• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Werewolf Therapeutics, Inc. - Common Stock (NQ:HOWL)

    0.6817 +0.0317 (+4.88%)
    Streaming Delayed Price Updated: 10:15 AM EST, Jan 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 24,169
    Open 0.6600
    Bid (Size) 0.6613 (500)
    Ask (Size) 0.6818 (500)
    Prev. Close 0.6500
    Today's Range 0.6600 - 0.6878
    52wk Range 0.5301 - 2.380
    Shares Outstanding 27,567,728
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Top movers in Thursday's session ↗
    Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
    Via Chartmill
    News headline image
    Keep an eye on the top gainers and losers in Thursday's session. ↗
    Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
    Via Chartmill

    Performance

    YTD
    +5.7%
    +5.7%
    1 Month
    +9.7%
    +9.7%
    3 Month
    -59.7%
    -59.7%
    6 Month
    -49.5%
    -49.5%
    1 Year
    -49.5%
    -49.5%

    More News

    Read More
    News headline image
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    One Patient's Complete Response to Investigational Cancer Therapy Sparks Hope
    Via Brandpoint
    News headline image
    Werewolf Therapeutics Announces Pipeline and Business Updates
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Monday? ↗
    Via Chartmill
    News headline image
    Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Reports No Revenue in Fiscal Q2 ↗
    Via The Motley Fool
    News headline image
    Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in the BIO International Convention
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Top movers in Tuesday's after hours session ↗
    Via Chartmill
    News headline image
    HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Werewolf Therapeutics to Participate in Upcoming Investor Conferences
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Werewolf Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Werewolf Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Werewolf Therapeutics, Inc. - Common Stock trade on?
    Werewolf Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Werewolf Therapeutics, Inc. - Common Stock?
    The ticker symbol for Werewolf Therapeutics, Inc. - Common Stock is HOWL on the Nasdaq Stock Market
    What is the current price of Werewolf Therapeutics, Inc. - Common Stock?
    The current price of Werewolf Therapeutics, Inc. - Common Stock is 0.6817
    When was Werewolf Therapeutics, Inc. - Common Stock last traded?
    The last trade of Werewolf Therapeutics, Inc. - Common Stock was at 01/27/26 10:15 AM ET
    What is the market capitalization of Werewolf Therapeutics, Inc. - Common Stock?
    The market capitalization of Werewolf Therapeutics, Inc. - Common Stock is 18.79M
    How many shares of Werewolf Therapeutics, Inc. - Common Stock are outstanding?
    Werewolf Therapeutics, Inc. - Common Stock has 19M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.